Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Alantos Pharmaceuticals raises $20 million & completes move to US


Cambridge, Massachusetts – March 10, 2005 -- Alantos Pharmaceuticals Holding, Inc., a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs with a focus on osteoarthritis/inflammation and type II diabetes, today announced it has raised $20 million in a series B private round of financing from existing investors Oxford Bioscience Partners, SV Life Sciences, Earlybird, ABN AMRO, Heidelberg Innovation and Ventech. Proceeds from the financing will be used to progress the Company’s pipeline of compounds, particularly its two lead candidates for diabetes and osteoarthritis into clinical development.

Alantos also announced the appointment of Frank L. Douglas, M.D., Ph.D., as Chairman of the Board. Until September 2004, Dr. Douglas was Executive Vice President of Aventis Pharma AG and head of Drug Innovation and Approval, with responsibilities for world wide discovery and development. He was also a member of the Board of Directors and Chief Scientific Officer of Aventis. Dr. Douglas is currently an Executive-in-Residence at MIT Sloan School of Management where he is establishing a Center for Biomedical Innovation.

“The current financing will allow us to take our lead programs in Osteoarthritis and Diabetes into the clinic and utilize our unique chemistry to expand our strong set of pre-clinical molecules primarily in inflammation,” said Keith Dionne, Ph.D., Chief Executive Officer of Alantos. “I am also excited to welcome Dr. Frank Douglas as Chairman of our Board. Frank’s extensive experience in pharmaceutical development, as well as his network across the pharmaceutical industry will be invaluable in developing our compounds internally and in working with pharmaceutical partners. ”

“I am eager to join Alantos at this junction in its development,” said Dr. Douglas. “The Company has identified exciting compounds with the potential to modify the disease progression of Osteoarthritis - one of the major unmet medical needs in the industry, as well as compounds with the potential to significantly impact adult onset diabetes. I look forward to working closely with Alantos as it continues to expand and implement its corporate initiatives.”

Separately, Alantos reported today that it has completed its incorporation in the United States. As a result, Alantos will move its headquarters to Cambridge, Massachusetts, while maintaining a research facility in Heidelberg, Germany. The Company has also announced that is has broadened its internal expertise with the appointments of Dr. Arthur Taveras as Vice President Medicinal Chemistry and Dr. Darrell J. Nix as Director, Pre-clinical Development.

“Alantos’ dual sites allow us to take advantage of superb chemistry and biology expertise in Germany, along with cost and in-licensing advantages of being in Europe; all the while having our headquarters and development in the largest biotech center of the U.S., with its corresponding access to financing, sector expertise and partnering,” said Dr. Dionne. “During the past year, Alantos has strategically built its infrastructure to support our growing pipeline of proprietary small molecules. I am excited to officially welcome both Dr. Taveras and Dr. Nix to the team, both whom have already made a significant impact in our lead programs.”

Arthur Taveras, Ph.D., joined Alantos from Schering-Plough Corporation where during his 14-year tenure he was responsible for medicinal chemistry and drug discovery activities in several anti-cancer and anti-inflammatory programs. Dr. Taveras was the inventor on nearly 50 U.S. patents and patent applications and has authored approximately 60 scientific publications/presentations. He received his Ph.D. and M.S. degrees in Synthetic Organic Chemistry and Natural Products Synthesis from Rensselaer Polytechnic Institute.

Darrell J. Nix, Ph.D., was most recently Associate Director, Pharmacokinetics and Drug Metabolism at Millennium Pharmaceuticals, Inc. where


Publisher Contact Information:

Alantos Pharmaceuticals AG
+1 917 322-2164
-

Company profile of Alantos Pharmaceuticals AG
Past press releases of Alantos Pharmaceuticals AG.

Data


27,147
Tech investments
From our Online Data Service
17,523
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Jul 23€23.0MArtificial Intelligence
Jul 22€20.0MKnowledge management
Jul 5€110.0MOther Biotechnology & Healthcare
Jul 5€13.0MInternet services
Jul 3€3.7MMedical devices
Jul 3€27.0MPayment software

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.